There has been a remarkable surge in the demand for medical thawing systems in various countries, owing to rise in cases of chronic diseases among people and surge in demand for blood and plasma products. Conversely, increase in awareness and government initiatives toward plasma donation and upsurge in the number of embryo donors are expected to drive the growth of the global medical thawing system market. According to the report published by Allied Market Research, the global medical thawing system market is expected to reach $279.17 million by 2027 with a CAGR of 11.6% from 2020 to 2027.
Numerous players in the market are launching new and innovative medical thawing system products in order to effectively cater to needs of people. For instance, Fremon Scientific, a medical device manufacturing company that specializes in efficacious processing of plasma, announced that its ZipThaw product has secured clearance from the U.S. Food and Drug Administration (FDA) as a Class 2 medical device for frozen plasma thawing.
ZipThaw is specially designed to use with the ZipSleeve (TM) anti-contaminant disposable barrier, which is claimed to be the world’s first dry and portable precision plasma thawing system. These products enable clinicians to deliver vital plasma to patients at the right time and temperature. ZipThaw and ZipSleeve have initially received CE Mark, ISO certification, and UL Listing. They received their FDA clearance for thawing fresh frozen plasma (FFP) and plasma frozen within 24 hours after phlebotomy. ZipThaw is capable of delivering plasma to patients who require transfusions.
With the help of ZipSleeve’s patented sensors, the system delivers accurate and degree-by-degree measurement of the specimen’s actual temperature during the thawing process, instead of its surroundings. One of the major perks of ZipThaw is that it does not require much maintenance as thawing is measured precisely and the end-to-end thawing process is easy to manage with a fewer technical staff. Farideh Bischoff, the Chief Executive Officer of FreMon Scientific, mentioned in a statement that they are delighted to receive the clearance from the FDA. The clearance will provide opportunities to facilitate clinicians with an effective device that can improve their patients’ lives.
The trend of launching creative medical thawing system products continues to gain massive momentum in the healthcare industry. For instance, General Electric (GE) Healthcare, a dominant company that provides digital infrastructure, data analytics, and decision support tools to help in diagnosis, treatment, and monitoring of patients, announced the launch of its new thawing technology called the VIA Thaw CB1000 in its VIA Thaw series for thawing large volumes of cell therapies that are cryopreserved in cryo-bags.
It is specially designed to get past the multiple inconsistent elements in standard water bath thawing practice as the impeccable VIA Thaw series delivers a convenient and reproducible recovery system that helps to maintain the viability of the cell to restrict the loss of therapeutic effect.
Thus, persistent and innovative product launches and technological advancements in medical thawing system market are expected to create ample opportunities for the growth of the market.